Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: The total number of infections climbed to 41,495. "In the past 24 hours we had 117 new deaths and 3,186 new confirmed cases of people infected with the coronavirus," Kianush Jahanpur told state TV, calling on Iranians to stay at home. Iran has had an intercity travel ban since Thursday and the government has extended the closure of universities and schools and the suspension of all cultural, religious and sports events. "If necessary, we might impose tougher measures as our priority is the nation's safety and health," said Iran's first Vice President, Eshaq Jahangiri, according to state TV. Iran last week warned of a surge of cases as many Iranians ignored calls to avoid traveling for Persian New Year holidays that started on March 20. To stem the spread of the virus in crowded jails, Iran's judiciary on Sunday extended furloughs for 100,000 prisoners. On March 17, Iran said it had freed about 85,000 people from jail temporarily, including political prisoners. Iranian media on Monday, citing the governor of Iran's Fars province, Enayatollah Rahimi, reported that prisoners at one prison "broke cameras and caused other damage in two sections of the prison where violent criminals are kept". The state news agency IRNA said similar riots had erupted in other prisons since March 20. Families have called for the release of all prisoners.
Example Output: Iran plans tougher restrictions as coronavirus toll rises.

Example Input: "In a press conference on May 5 in which Gov. Greg Abbott updated his reopening plan to add businesses such as hair salons and gyms, he recommended that at-risk populations ""remain at home if at all possible"" and avoid in-person gatherings, such as a church service, funeral or wedding. ""We strongly encourage at-risk populations to try to watch or participate remotely, remembering this very important point, and that is almost 75 percent of the deaths from COVID-19 in the state of Texas are a result of people contracting COVID-19 who are age 65 and older,"" Abbott said. Texas was among the first states to start reopening businesses and lifting restrictions put in place to curb the spread of the coronavirus, allowing retail stores and restaurants to open May 1 at 25 percent capacity. Abbott announced the latest set of reopenings Monday, expanding restaurant capacity to 50 percent and granting bars the ability to open at 25 percent capacity within the next couple weeks. This comes as the state continues to see its number of infections and deaths rise and clusters form mostly in rural parts of the state where meatpacking plants are located. Hospitalizations, however, have decreased since mid-April. With that in mind, we had to ask: Is Abbott right that almost 75% of coronavirus deaths in Texas are people older than 65? Looking at the numbers Abbott's spokesman John Wittman said Abbott's claim is based on figures from the Texas Department of Health Services, which publishes daily numbers on the state's COVID-19 testing and cases. The data includes a breakdown of coronavirus deaths by age, race and gender, but only for those cases where the deaths have been investigated by the local and regional health departments. As of Wednesday, the majority, or 489, were still under investigation. ""The demographic data on cases and fatalities come from the case investigation forms submitted by local health departments and our regional offices,"" said DSHS spokesman Chris Van Deusen. The purpose of the investigation is to confirm that the person had COVID-19 but also to collect other details about them and the circumstances around their death, Van Deusen said. Wittman said the data showed that 75% of investigated deaths were people 65 and older when Abbott made this statement. ""It alternates almost daily, but it's generally around that range,"" Wittman said. As of May 6, the day after the press conference, the death toll in Texas was 948. Fewer than half, or 433, had been investigated. Of those, about 71 percent were Texans 65 and older. It was still about 71 percent, or 345 out of 489 investigated cases, as of Wednesday. The age groups broke down like so: Ages 10 to 19 years old: 2 deaths, or 0.4% Ages 20-29: 10 deaths, or 2.04 % Ages 30-39: 9 deaths, or 1.8% Ages 40-49: 21 deaths, or 4.29% Ages 50-59: 54 deaths, or 11.04% Ages 60-64: 45 deaths, or 9.2% Ages 65-69: 59 deaths, or 12.06% Ages 70-74: 45 deaths, or 9.2% Ages 75-79: 45 deaths, or 9.2% Ages 80+: 196 deaths, or 40.08% Across the United States, about 79% of coronavirus deaths have been people 65 years and older, according to the National Center for Health Statistics data submitted between the beginning of February to the beginning of May. Like Texas' statistics, the national numbers are also incomplete. The number of deaths represent only those entered between those dates and only include people with confirmed or presumed COVID-19. ""While 80% of deaths are electronically processed and coded by NCHS within minutes, most deaths from COVID-19 must be coded by a person, which takes an average of 7 days,"" the NCHS states on its website. The data is also always somewhat behind because of the lag time between when a death occurred and when a death certificate is completed, submitted to NCHS and processed for reporting purposes. The delay can last anywhere from one week to eight or more. Our ruling Abbott said almost ""75 percent of the deaths from COVID-19 in the state of Texas are a result of people contracting COVID-19 who are age 65 and older."" Of confirmed coronavirus deaths, close to 75% were people within the age group Abbott provided, but he failed to include the caveat that this statistic leaves out more than half of the total deaths that have not yet been investigated."
Example Output: "Almost 75 percent of the deaths from COVID-19 in the state of Texas are a result of people contracting COVID-19 who are age 65 and older."

Example Input: There is no mention of the cost of this new drug, Rydapt (midostaurin), or of the cost of the diagnostic tool, theLeukoStrat CDx FLT3 Mutation Assay, which the FDA approved for use in determining the appropriateness of using this drug. Many patients will need to be tested for this mutation in order to find the individuals who have it and thus may benefit from this new drug. However, the FDA evaluates drugs without considering costs, which is why they are not discussed in this news release. Although the release does provide some numerical context, it's insufficient to give credit here. The release could have provided much more useful information about the quantitative benefits. For example, a summary of the trial upon which the approval was based stated, "At a median follow-up of 57 months, midostaurin reduced mortality risk by 23% compared with placebo plus chemotherapy. The median OS was 74.7 months for the group receiving midostaurin versus 26 months for the placebo group (P = .007), representing a 23% reduction in the risk for death favoring midostaurin." The release should have provided both absolute as well as relative benefits, both of which were available from the trials. What the release does say is that patients who received a combinationof standard chemotherapy and Rydapt for treating AML "lived longer than patients who received chemotherapy alone, although a specific median survival rate could not be reliably estimated," compared to patients receiving chemotherapy plus a placebo. That's pretty vague. In addition, it said that "patients who received Rydapt in combination with chemotherapy in the trial went longer (median 8.2 months) without certain complications (failure to achieve complete remission within 60 days of starting treatment, progression of leukemia or death) than patients who received chemotherapy alone (median three months)." The release effectively reports possible side effects experienced by AML patients receiving Rydapt, including "low levels of white blood cells with fever (febrile neutropenia), nausea, inflammation of the mucous membranes (mucositis), vomiting, headache, spots on the skin due to bleeding (petechiae), musculoskeletal pain, nosebleeds (epistaxis), device-related infection, high blood sugar (hyperglycemia) and upper respiratory tract infection." It also warns women who are pregnant or breastfeeding to avoid taking Rydapt. It also points out that the FDA approved the use of Rydapt for other patients with "certain types of rare blood disorders" and provides a list of possible side effects they might experience. The release explains that the approval follows the completion of a "randomized trial of 717 patients who had not been treated previously for AML." It would have been better if the release would have added how many patients were screened with the diagnostic test to identify the 717 patients studied. While it appears this treatment prolongs survival, it isn't clear from the release what the time frame is, meaning people may live longer but still may die in the end of the disease. And while the release states that there are almost 20,000 patients diagnosed with AML each year in the US, it doesn't state how many may have this mutation and thus be potentially treated with this new therapy. According to a review article published last year, "Approximately 30% of patients with AML carry the FLT3 mutation, which is associated with aggressive disease, with poor prognosis and a high risk for relapse." That means that most patients with AML will not be eligible for this treatment but the release could give the general public the impression that it will help most patients with AML. There is no evidence of disease mongering here. AML is a life-threatening condition and new agents that can prolong life are clearly needed. There's plenty of context about the disease and how the drug works: "Rydapt is a kinase inhibitor that works by blocking several enzymes that promote cell growth. If the FLT3 mutation is detected in blood or bone marrow samples using the LeukoStrat CDx FLT3 Mutation Assay, the patient may be eligible for treatment with Rydapt in combination with chemotherapy." The release doesn't mention who funded the research leading to the approval, although some readers might be able to guess that Novartis Pharmaceuticals, the manufacturer of Rydapt, and Invivoscribe Technologies, the makers of the LeukoStrat CDx FLT3 Mutation Assay, sponsored the trials since the approval was given to them. The new medication was used in combination with standard chemotherapy. That tells us the alternative was standard chemotherapy alone, an important comparison. While the release doesn't specifically state the availability of the drug, the FDA approval for its use suggests that it should start to become available in a matter of months and not years. The release makes clear that the use of this drug for AML patients with the FLT3 mutation is a new approach for a situation where previous therapies have been marginally successful. It also claims that thedrug is "the first targeted therapy to treat patients with AML, in combination with chemotherapy," according to an FDA official. No unjustifiable language here.
Example Output:
FDA approves new combination treatment for acute myeloid leukemia